Novo Nordisk A/S (NYSE:NVO) Shares Bought by Dillon & Associates Inc.

Dillon & Associates Inc. grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 283,417 shares of the company’s stock after purchasing an additional 1,271 shares during the quarter. Novo Nordisk A/S comprises about 4.7% of Dillon & Associates Inc.’s investment portfolio, making the stock its 3rd biggest position. Dillon & Associates Inc.’s holdings in Novo Nordisk A/S were worth $33,727,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. GQG Partners LLC increased its stake in Novo Nordisk A/S by 654.6% in the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after acquiring an additional 3,151,584 shares during the period. International Assets Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Novo Nordisk A/S by 1,300.8% in the first quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock valued at $159,703,000 after buying an additional 1,155,313 shares during the period. Finally, Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S in the third quarter valued at approximately $98,765,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several analyst reports. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Down 1.9 %

NVO opened at $107.05 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $480.39 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 1.32 and a beta of 0.42. The company’s 50 day moving average price is $120.82 and its two-hundred day moving average price is $130.22.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.